Introducing the Virtual KOL Event on Sirexatamab
Leap Therapeutics, Inc. (NASDAQ: LPTX) is excited to announce an engaging virtual key opinion leader (KOL) event that aims to spotlight the advancements surrounding sirexatamab, particularly in second-line patients with advanced microsatellite stable colorectal cancer (MSS CRC). This event promises to provide valuable insights from leading experts in the oncology field.
Focus of the Event
The virtual KOL event is set to take place soon, where renowned oncologist Dr. Zev A. Wainberg from UCLA will lead an enlightening discussion on the unmet clinical needs in this area. Dr. Wainberg's experience and expertise will help bridge the gap in understanding how sirexatamab might transform the treatment landscape for previously treated MSS CRC patients.
Why Sirexatamab?
Sirexatamab (DKN-01) stands out as Leap Therapeutics’ most advanced clinical program. It is a humanized monoclonal antibody specifically designed to target the Dickkopf-1 (DKK1) protein, which plays a significant role in the progression of various tumors. The event will delve into positive findings from Part B of the Phase 2 DeFianCe study, shedding light on its efficacy in combating advanced MSS CRC.
Join the Conversation
After Dr. Wainberg shares insights alongside Leap's Chief Medical Officer, Dr. Cynthia Sirard, there will be a live question and answer session. This interactive component allows participants to engage directly with the experts, providing a unique platform for discussion.
The Importance of the Research
The conversation will revolve around the data from clinical trials that illustrate the potential benefits of sirexatamab for patients suffering from this challenging condition. Researchers and clinicians alike will find the analyses of these trials invaluable as they consider future therapeutic options for their patients.
About Dr. Zev A. Wainberg
Dr. Wainberg is highly regarded for his contribution to oncology. As the co-director of the UCLA GI Oncology Program, he focuses on gastrointestinal malignancies. His comprehensive research encompasses various clinical trials, targeting innovative therapies against a spectrum of gastrointestinal cancers. His accomplishments solidify his authority in the field, making his input during the event particularly noteworthy.
About Leap Therapeutics
Leap Therapeutics is dedicated to advancing targeted and immuno-oncology therapeutics. With a commitment to improving treatment outcomes, the company’s lead candidate, sirexatamab (DKN-01), is under rigorous study for its potential efficacy in colorectal cancer patients. Alongside sirexatamab, Leap’s pipeline includes FL-501, a monoclonal antibody in preclinical stages, aimed at addressing cancer through innovative approaches.
Future Developments
As Leap Therapeutics navigates the complex landscape of cancer treatment, the insights gathered during the KOL event will serve to inform ongoing research and future clinical trials. The anticipated discussions will highlight both the challenges and the exciting advancements in the field, paving the way for enhanced patient outcomes.
Frequently Asked Questions
What is the main focus of the upcoming event?
The event will primarily discuss the advancements and clinical efficacy of sirexatamab (DKN-01) in treating patients with advanced microsatellite stable colorectal cancer.
Who will be speaking at the event?
Dr. Zev A. Wainberg, a prominent oncologist from UCLA, will lead the discussions along with Leap's Chief Medical Officer, Dr. Cynthia Sirard.
How can I register for the event?
Details on registration can be found on Leap Therapeutics' official website.
What are the key benefits of sirexatamab?
Sirexatamab is engineered to target the DKK1 protein, which is significant in tumor biology, aiming to enhance treatment options for colorectal cancer patients.
Is there a replay available after the event?
Yes, a replay of the virtual KOL event will be made available on the Investors page of Leap Therapeutics’ website for a limited time.
